Earnings Releases·Oct 29, 2026, 6:50 AM ET

Pediatrix Medical Group — Q3 2026 Earnings Summary

Net revenue increased 1.7% year-over-year to $501.4 million for the quarter, though net income declined 34% to $47.0 million ($0.59/share) due to a $20.9 million reduction in net gains from divested businesses and higher practice salaries.
Full-year 2026 Adjusted EBITDA guidance remains unchanged at $290 million to $300 million, supported by 1.1% growth in non-same unit revenue and a favorable 70 basis point shift toward commercial payors.
Capital allocation included $83.0 million in share repurchases, reducing weighted average shares to 79.7 million, while cash balances decreased to $311.9 million and total debt remained stable at $578 million.
Operational drivers included a 0.6% same-unit revenue increase and 2.9% growth in office-based patient volume, partially offset by a 0.3% decline in hospital-based services and rising G&A expenses.